Sorafenib and Mek Inhibition are Synergistic in Medullary Thyroid Carcinoma in Vitro

1 Divisions of Endocrinology, Diabetes and Metabolism 1 , Medical Oncology 2 , Department of Chemistry 3 , Center for Biostatistics 4 , and Department of Molecular Virology, Immunology and Genetics 5 , The Ohio State University Medical Center, The Ohio State University and The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH, USA; 6 Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea; 7 Department of Otolaryngology, Head and Neck Surgery, Chungnam National University, Daejoon, Korea.